Sugi Predict

Sugi Predict / Compounds / SCHEMBL19252141

SCHEMBL19252141

SCHEMBL19252141

O=[N+]([O-])c1cccc2c1cc(I)n2CC(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 1/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ DCTPP1 Q9H773 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ MAPT P10636 5/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ GAA P10253 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ POLB P06746 2/20 0.33
▸ RORA P35398 1/20 0.33
▸ RORC P51449 1/20 0.33
▸ RORB Q92753 1/20 0.33
▸ GPR35 Q9HC97 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ P2RX1 P51575 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29876445 1.00 CCR2 (0.41) CCR2TDP1DCTPP1ALDH1A1MAPT
SCHEMBL26378306 0.90 CCR2 (0.40) CCR2TDP1DCTPP1ALDH1A1MAPT
SCHEMBL23144709 0.87 CCR2 (0.40) CCR2TDP1DCTPP1ALDH1A1MAPT
SCHEMBL29812153 0.87 CCR2 (0.40) CCR2TDP1DCTPP1ALDH1A1MAPT
SCHEMBL23144629 0.81 CCR2 (0.41) CCR2TDP1ALDH1A1MAPTMEN1
SCHEMBL29812160 0.81 CCR2 (0.41) CCR2TDP1ALDH1A1MAPTMEN1
SCHEMBL26380619 0.77 MAPT (0.36) DCTPP1ALDH1A1MAPTMEN1KMT2A
SCHEMBL30295610 0.77 CCR2 (0.46) CCR2TDP1DCTPP1ALDH1A1MAPT
SCHEMBL19252451 0.76 ALDH1A1 (0.33) TDP1ALDH1A1MAPTMEN1KMT2A
SCHEMBL23155546 0.76 METAP2 (0.35) MAPTMEN1KMT2AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014261-A1 TARGETED PROTEIN MODIFICATION WEATHERWAX BIOTECHNOLOGIES CORP (US) 2026-01-15 — — US disclosed
WO-2024112611-A1 TARGETED PROTEIN MODIFICATION WEATHERWAX BIOTECHNOLOGIES CORPORATION (US) 2024-05-30 — — WO disclosed
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2024-02-08 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
EP-4149459-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-03-22 — — EP disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 — — US disclosed
US-20220213062-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2022-07-07 — — US disclosed
US-11339141-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
WO-2021231474-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-11-18 — — WO disclosed
US-20210002252-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2021-01-07 — — US disclosed
US-10640485-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2020-05-05 — — US disclosed
US-20190119249-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2019-04-25 — — US disclosed
EP-3416638-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2018-12-26 — — EP disclosed
CN-109069481-A Methods and compounds for restoring function of mutant p53 皮姆维制药公司 2018-12-21 — — CN disclosed
US-10138219-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS (US) 2018-11-27 — — US disclosed
US-20170240525-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2017-08-24 — — US disclosed
WO-2017143291-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2017-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170240525-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS CCR2 3546/4885TDP1 92/4885DCTPP1 480/4885
US-11339141-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS CCR2 3546/4885TDP1 92/4885DCTPP1 480/4885
US-20220213062-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS CCR2 3546/4885TDP1 92/4885DCTPP1 480/4885
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS CCR2 4114/4885TDP1 55/4885DCTPP1 384/4885
US-20190119249-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS CCR2 3546/4885TDP1 92/4885DCTPP1 480/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS CCR2 4114/4885TDP1 55/4885DCTPP1 384/4885
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS CCR2 4114/4885TDP1 55/4885DCTPP1 384/4885
US-10640485-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS CCR2 3546/4885TDP1 92/4885DCTPP1 480/4885
US-20210002252-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS CCR2 3546/4885TDP1 92/4885DCTPP1 480/4885
US-20260014261-A1 TARGETED PROTEIN MODIFICATION MDM2, TP53, VHL CCR2 3999/4885TDP1 1244/4885DCTPP1 3134/4885
US-10138219-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS CCR2 3546/4885TDP1 92/4885DCTPP1 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.